Rubin P H
Deparment of Economics and School of Law, Emory University, Atlanta, Georgia, USA.
J Biolaw Bus. 2001;4(4):59-65.
Pharmaceutical companies have greatly increased their level of "direct-to-consumer" (DTC) advertising in recent years. For 1998, estimates are that over $1.1 billion was spent on this form of advertising, increased from $850 million in 1997 and $600 million in 1996. In 1998, 84 separate drugs were advertised to consumers. The impetus was a decision in August of 1997 by the Food and Drug Administration to reduce the restrictions on DTC advertising on television. As a result, such ads have become very common on TV, and 32 products were advertised on TV in 1998. Pharmaceutical companies advertise because they think that advertising will make money for them. But how will this make money? It will make money by providing consumers with the information they need to make proper decisions about medication. That is, DTC advertising is profitable exactly because it empowers consumers and enables them to purchase useful drugs. The goals of advertising companies and consumers are both for consumers to have information about the most beneficial drug for particular conditions, and so advertising is beneficial both to manufacturers and to consumers. This article describes emerging trends in DTC within the context of the life sciences sector.
近年来,制药公司大幅增加了“直接面向消费者”(DTC)的广告投放量。据估计,1998年用于这种广告形式的花费超过11亿美元,高于1997年的8.5亿美元和1996年的6亿美元。1998年,有84种不同的药品向消费者做了广告。推动这一现象的是美国食品药品监督管理局在1997年8月做出的一项决定,即放宽对电视上DTC广告的限制。结果,此类广告在电视上变得非常普遍,1998年有32种产品在电视上做了广告。制药公司做广告是因为他们认为广告能为他们带来收益。但这是如何盈利的呢?它通过向消费者提供做出正确用药决策所需的信息来盈利。也就是说,DTC广告之所以有利可图,恰恰是因为它赋予了消费者权力,使他们能够购买有用的药品。广告公司和消费者的目标都是让消费者了解针对特定病症最有益的药物信息,所以广告对制造商和消费者都有益。本文将在生命科学领域的背景下描述DTC广告的新趋势。